Drug‐induced immune‐mediated thrombocytopenia secondary to durvalumab use
نویسندگان
چکیده
منابع مشابه
Life-Threatening Thrombocytopenia Secondary to Trimethoprim/Sulfamethoxazole
Thrombocytopenia is an uncommon side effect of trimethoprim/sulfamethoxazole (TMP/SMX) when given in the usual recommended adult dosage. We report a case of severe and possibly life-threatening thrombocytopenia associated with TMP/SMX therapy. A 92-year-old female presented after a mechanical fall and subsequent intractable bleeding from a laceration on her left leg. She had a history of cellul...
متن کاملThrombocytopenia secondary to linezolid administration: what is the risk?
tration was stopped on day 21. The WBC count and the platelet count reached nadir 4 days after discontinuation of linezolid (to cells/mL and plate3 3 3.3 10 55 10 lets/mL, respectively); the platelet count returned to a level 1 platelets/mL 3 100 10 only 7 days after administration of the drug ceased. The hemoglobin level decreased to 7.9 g/dL 7 days after linezolid therapy was stopped; there w...
متن کاملImmune Thrombocytopenia (ITP) Secondary to Subclinical Hashimoto’s Thyroiditis
Immune thrombocytopenia (ITP) is the most common cause of isolated thrombocytopenia in healthy people. ITP may rarely coexist with autoimmune thyroid disorders, which may indicate more complex defect in immune system. Primary ITP usually responds well to steroids and intravenous immunoglobulins. However, ITP may be difficult to treat when associated with thyroid autoimmune disorders. In such ca...
متن کاملBilateral Spontaneous Hemotympanum Secondary to Chemotherapy-Induced Thrombocytopenia
OBJECTIVE To present a case of spontaneous, bilateral hemotympanum secondary to chemotherapy-induced thrombocytopenia. METHODS Case report and review of the literature. RESULTS Bilateral spontaneous hemotympanum is an exceedingly rare event. We present the first case of nontraumatic bilateral hemotympanum secondary to chemotherapy-induced thrombocytopenia in a patient with acute myelogenous...
متن کاملAcute profound thrombocytopenia secondary to local abciximab infusion.
Glycoprotein (GP) IIb/IIIa receptor antagonists are powerful antiplatelet agents that are typically used in percutaneous coronary intervention. All three GP IIb/IIIa agents currently approved for use in the United States cause thrombocytopenia as a rare side effect. Abciximab is unique to the class in that it is a modified monoclonal antibody to the GP IIb/IIIa receptor, a property that can lea...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Case Reports
سال: 2021
ISSN: 2050-0904,2050-0904
DOI: 10.1002/ccr3.4227